Detail akcie Adagene Sp ADS online

Business Summary: Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Adagene Inc (ADR) revenues was not reported. Net loss decreased 21% to $13.5M. Lower net loss reflects Pharmaceuticals Preparations segment loss decrease of 14% to $15.7M, China (Mainland) segment loss decrease of 14% to $15.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.31 to -$0.23.